IONIS-AGT-LRx is an investigational ligand-conjugated antisense (LICA) medicine designed to inhibit the production of angiotensinogen to decrease blood pressure in people with chronic heart failure with reduced ejection fraction.
About Chronic Heart Failure with Reduced Ejection Fraction
Heart failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen. HF with reduced ejection fraction is a clinical syndrome of shortness of breath, exercise intolerance and/or fluid retention resulting from an impairment of ejection of blood, usually documented by a left ventricular ejection fraction of 40 percent or less on echocardiography.
Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.